This is an international site for Sandostatin® LAR® and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

Sandostatin LAR Information for US residents Sandostatin LAR Information for International Healthcare Professionals Sandostatin LAR Information for Patients Outside the US
Sandostatin® LAR® Delivers Powerful Efficacy and Unparalleled Evidence

Home > Treating Acromegaly  > Treatment and Management of Acromegaly > Efficacy of Sandostatin® LAR® in Acromegaly

Efficacy of Sandostatin® LAR® in Acromegaly

Sandostatin LAR is the most prescribed and most studied medical therapy in the treatment of acromegaly. Sandostatin LAR has a well-established safety profile backed by more than a decade of clinical use.1,2

Sandostatin LAR works centrally at the site of the tumour and binds to somatostatin receptors to regulate GH secretion and cell growth.3

  • 96% of GH-secreting pituitary tumours express the somatostatin receptor subtype, sst24

Sandostatin LAR works directly at the tumour site to reduce pituitary tumour size5,6

GH levels are the single most important determinant of mortality in acromegaly.7

  • Mortality rates are improved or normalised in acromegaly patients with posttreatment GH levels <2.5 ng/mL5

The goal of therapy is to reduce both GH and IGF-1 levels.5

  • Sandostatin LAR delivers effective control of both GH and IGF-1 levels5,6

Sandostatin® LAR® delivers effective control of both GH and IGF-1 levels

Symptom control is an important therapeutic goal in acromegaly.5

Sandostatin LAR delivers significant improvement in 5 common symptoms of acromegaly.8

Sandostatin® LAR® provides symptom control in Acromegaly

Click here for Important Safety Information for SANDOSTATIN LAR

References: 1. Data on file, Novartis Pharma AG. 2. PubMed [database online]. National Center for Biotechnology Information. Available at: http://www.ncbi.nlm.nih.gov/sites/gquery?term=sandostatin. Accessed March 19, 2009. 3. Paisley AN, Trainer PJ. Medical treatment in acromegaly. Curr Opin Pharmacol. 2003;3:672-677. 4. Hofland LJ, Lamberts SWJ. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev. 2003;24:28-47. 5. Cozzi R, Attanasio R, Montini M, et al. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab. 2003;88:3090-3098. 6. Mercado M, Borges F, Bouterfa H, et al; on behalf of the SMS995B2401 Study Group. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol. 2007;66:859-868. 7. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab. 2000;85:526-529. 8. Lancranjan I, Atkinson AB; for the Sandostatin® LAR® Group. Results of a European Multicentre Study with Sandostatin® LAR® in acromegalic patients. Pituitary. 1995;1:105-111.